Javier Bolanos-Meade
Overview
Explore the profile of Javier Bolanos-Meade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
4758
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gooptu M, Bolanos-Meade J, Koreth J
Blood Rev
. 2023 Feb;
62:101053.
PMID: 36822991
No abstract available.
12.
Saad A, Loren A, Bolanos-Meade J, Chen G, Couriel D, Di Stasi A, et al.
J Natl Compr Canc Netw
. 2023 Feb;
21(2):108-115.
PMID: 36791762
The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult...
13.
Webster J, Reed M, Tsai H, Ambinder A, Jain T, DeZern A, et al.
Transplant Cell Ther
. 2023 Jan;
29(3):182.e1-182.e8.
PMID: 36587740
Patients age ≥55 years with acute lymphoblastic leukemia (ALL) fare poorly with conventional chemotherapy, with a 5-year overall survival (OS) of ∼20%. Tyrosine kinase inhibitors and novel B cell-targeted therapies...
14.
Shaw B, Jimenez-Jimenez A, Burns L, Logan B, Khimani F, Shaffer B, et al.
Transplant Cell Ther
. 2022 Dec;
29(3):208.e1-208.e6.
PMID: 36584941
The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has resulted in reductions in GVHD and improved outcomes in allogeneic hematopoietic cell transplantation (HCT) using HLA-mismatched related donors....
15.
Sterling C, Hughes M, Tsai H, Yarkony K, Fuchs E, Swinnen L, et al.
Transplant Cell Ther
. 2022 Dec;
29(4):267.e1-267.e5.
PMID: 36549386
The use of post-transplantation cyclophosphamide (PTCy) for graft-versus host-disease (GVHD) prophylaxis has revolutionized allogeneic blood or marrow transplantation (alloBMT), but there is limited published experience in peripheral T cell lymphoma...
16.
Porter T, Lazarevic A, Ziggas J, Fuchs E, Kim K, Byrnes H, et al.
Br J Haematol
. 2022 Sep;
199(5):720-727.
PMID: 36111395
Haemophagocytic lymphohistiocytosis-like toxicity following chimeric antigen receptor T cells (CAR-HLH) is being increasingly recognized, while published data are limited and criteria for recognition are elusive. We describe three patients who...
17.
Hughes M, Sterling C, Varadhan R, Ambinder R, Jones R, Sweren R, et al.
Leuk Lymphoma
. 2022 Aug;
63(12):2987-2991.
PMID: 35915978
No abstract available.
18.
Jain T, Tsai H, DeZern A, Gondek L, Elmariah H, Bolanos-Meade J, et al.
Transplant Cell Ther
. 2022 Feb;
28(5):259.e1-259.e11.
PMID: 35158092
We describe outcomes after post-transplantation cyclophosphamide and nonmyeloablative conditioning-based allogeneic blood or marrow transplantation for myelofibrosis using matched or mismatched related or unrelated donors. The conditioning regimen consisted of fludarabine,...
19.
Ambinder A, Smith M, Tsai H, Varadhan R, DeZern A, Dalton W, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Nov;
22(4):260-269.
PMID: 34750086
Introduction: Mutations in the IDH1 or IDH2 genes are detected in approximately 20% of cases of acute myeloid leukemia (AML). Few studies have examined the impact of IDH mutations in...
20.
Kanter J, Liem R, Bernaudin F, Bolanos-Meade J, Fitzhugh C, Hankins J, et al.
Blood Adv
. 2021 Sep;
5(18):3668-3689.
PMID: 34581773
Background: Sickle cell disease (SCD) is a life-limiting inherited hemoglobinopathy that results in significant complications and affects quality of life. Hematopoietic stem cell transplantation (HSCT) is currently the only curative...